RTP Mobile Logo
Select Publications

Bendell JC et al. CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). Gastrointestinal Cancers Symposium 2021;Abstract TPS449.

Burris HA et al. A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. ASCO 2021;Abstract 2516.

Camidge DR et al. Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. J Thorac Oncol 2021;16(12):2091-108. Abstract

Carrizosa DR et al. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NGR1 fusions. ASCO 2022;Abstract 3006.

Cho BC et al. Phase 1/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors. IASCL 2021;Abstract 3255.

Demetri GD et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 2022;28(7):1302-12. Abstract

Denlinger CS et al. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs 2021;39(6):1604-12. Abstract

Drilon A et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383(9):813-24. Abstract

Drilon A et al. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC. JTO Clin Res Rep 2022;3(6):100332. Abstract

Drilon A et al. ROS1-dependent cancers - Biology, diagnostics and therapeutics. Nat Rev Clin Oncol 2021;18(1):35-55. Abstract

Drilon A et al. Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. ASCO 2022;Abstract 9024.

Dy GK et al. Long-term outcomes with sotorasib in pre-treated KRAS p.G12C mutated NSCLC: 2-year analysis of CodeBreaK 100. AACR 2022;Abstract CT008.

Dziadziuszko R et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol 2021;39(11):1253-63. Abstract

Gainor JF et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22(7):959-69. Abstract

Horn L et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial. JAMA Oncol 2021;7(11):1617-25. Abstract

Janne PA et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 2022;387(2):120-31. Abstract

Judd J et al. Characterization of KRAS mutant subtypes in non-small cell lung cancer. Mol Cancer Ther 2021;20(12):2577-84. Abstract

Krebs MG et al. Amivantamab in NSCLC patients with MET exon 14 skipping mutation: Updated results from the CRYSALIS study. ASCO 2022;Abstract 9008.

Le X et al. Landscape and clonal dominance of co-occurring genomic alterations in non-small-cell lung cancer harboring MET exon 14 skipping. JCO Precis Oncol 2021;5:PO.21.00135. Abstract

Le X et al. Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin Cancer Res 2022;28(6):1117-26. Abstract

Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract

Liu SV. NGR1 fusions: Biology to therapy. Lung Cancer 2021;158:25-8. Abstract

Liu SV et al. Efficacy of afatinib in patients with advanced/metastatic solid tumors harboring NRG1 gene fusions: A novel, prospective real-world outcomes study based on single-patient protocol data. ASCO 2022;Abstract TPS3180.

Marmarelis ME et al. Treatment patterns and outcomes in ALK or ROS1 altered NSCLC: An ATOMIC registry study. ASCO 2022;Abstract 9077.

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract

Nagasaka M et al. The effects of HER2 alterations in EGFR mutant non-small-cell lung cancer. Clin Lung Cancer 2022;23(1):52-9. Abstract

Peters S et al. Efficacy and safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the blood first assay screening trial (BFAST). ASCO 2022;Abstract LBA9023.

Popat S et al. Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naïve ALK+ NSCLC: Final results from ALTA-1L. ESMO 2021;Abstract 1195P.

Reuss JE et al. Antibody drug conjugates in lung cancer: State of the current therapeutic landscape and future developments. Clin Lung Cancer 2021;22(6):483-99. Abstract

Schubert L et al. Incidence of ERBB gene fusions (EGFR, ERBB2, ERBB4) across tumor types. ASCO 2021;Abstract 3091.

Tan AC, Tan SWT. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40(6):611-25. Abstract

Wolf J et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. ASCO 2021;Abstract 9020.

Yeung V et al. Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: A case report. Transl Lung Cancer Res 2022;11(1):111-6. Abstract